Kura Oncology-backed Caspian advances KO-7246 menin inhibitor toward first-in-human diabetes trials

• Kura Oncology highlighted new preclinical results for KO-7246, positioning it as a menin inhibitor aimed at restoring insulin-producing beta-cell function.
• Data were presented at the European Association for the Study of Diabetes meeting, with an investor webcast scheduled for Oct. 13, 2026.
• Studies showed durable glycemic control with effects that persisted after dosing ended, supporting a potential disease-modifying profile in diabetes models.
• Results also indicated selective beta-cell regeneration in human islets, with potential to complement GLP-1 therapy based on combination findings.
• Kura’s Caspian Therapeutics unit is advancing KO-7246 through IND-enabling work toward initial clinical evaluation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290515PRIMZONEFULLFEED9835632) on September 29, 2026, and is solely responsible for the information contained therein.